COVID-19 Update for 6/2/2020

Remdesivir
 
Gilead announced that in the first 585 patients enrolled in an 11-day, Phase III trial (NCT04292730), patients treated with a 5-day course of remdesivir were 65% more likely to have at least a 1-point improvement on a seven-point scale that runs from death to not hospitalized in hospitalized patients with moderate COVID-19. A 10-day course of remdesivir did not differ from placebo in the treatment of moderate COVID-19 patients.
 
COVID-19 Antibodies 
 
Lilly initiated a Phase I trial to evaluate a single dose of LY-CoV555 as a treatment for hospitalized COVID-19 patients at the beginning of June. Results are expected by the end of June and positive results will lead to a Phase II trial. LY-CoV555 is a neutralizing IgG1 monoclonal antibody targeting the spike protein of SARS-CoV-2. AbCellera and NIAID identified the antibody from a COVID-19 patient and Lilly developed a way to produce the antibody.

COVID-19 Vaccine

Moderna initiated a 600 patient, Phase II trial in late May. Patients will be given two doses 28-days apart of mRNA-1273 vaccine low dose (50 micrograms), high dose (100 micrograms) or placebo. Half of the patients enrolled in the trial will be older than 55. The Phase III trial is expected to begin in July 2020. Moderna hopes to file a BLA for mRNA-1273 in early 2021.